Latest News

Associate Professor Michael J. Campion, TruScreen Medical Advisory Committee member, sits down to discuss the science behind TruScreen's Cervical Cancer Screening Device, it's clinical validation…

Cervical cancer technology company, TruScreen Limited (NZAX:TRU), advises that it wishes to provide to shareholders a copy of its latest investor presentation.

VIDEO: TS in Russia - Chechnya Hospital Visit, March 2020

Despite considerable progress in the past decades, societies continue to fail to meet the healthcare needs of women at key moments in their lives.

TruScreen Limited (NZX:TRU) is pleased to announce the appointment of Ms Victoria Potarina as Chief Executive Officer, commencing 2 March 2020.

Cervical cancer is epidemic in India, with 77,300 new cases diagnosed each year and 37,800 deaths resulting from the disease—a fatality rate of 49 per…

China manufacturing approvals expected to provide TruScreen greater market access. Local manufacturing contracts in China under negotiation with expected reduction in component costs. Novel Coronavirus…